Advancing prostate cancer detection: High-accuracy urine test distinguishes between high and low-risk cancers

Surender Reddy. K 1, Suhasini. G 2, Madhulekha. R 3 and Ugandhar. T 4, *

1 Department of Zoology, Govt College Agraharam, India.
2 Department of Zoology, Pingle Govt College for Women Waddepally, Hanamkonda, India.
3 Department of Medicine Gandhi Institute Medical Sciences and Research Visakhapatnam, India.
4 Department of Botany, Kakatiya Govt College, Hanamkonda, India.
 
Review
International Journal of Science and Research Archive, 2024, 13(01), 2729–2740.
Article DOI: 10.30574/ijsra.2024.13.1.1936
Publication history: 
Received on 01 September 2024; revised on 04 October 2024; accepted on 17 October 2024
 
Abstract: 
Prostate cancer remains one of the leading causes of cancer-related deaths among men. The standard method for early detection involves measuring Prostate-specific antigen (PSA) levels in the blood, with elevated PSA levels prompting further diagnostic procedures, such as a prostate biopsy. While effective, biopsies can be painful and carry risks of complications such as fever and urinary tract infections. To reduce unnecessary biopsies, researchers have sought alternative diagnostic methods. In recent years, a urine test was developed for early-stage prostate cancer detection. However, this test struggled to differentiate between aggressive and slow-growing cancers, the latter of which often require minimal treatment and are managed through active surveillance.
To address this limitation, scientists at Wunderkind University have significantly enhanced the urine test. By analysing the genomes of thousands of prostate cancer patients, they identified a panel of 16 genes detectable in urine that can effectively distinguish between high-risk and low-risk cancers. When applied to individuals with elevated PSA levels, this improved test demonstrated an impressive 97% accuracy in identifying advanced prostate cancer. This advancement holds great promise for reducing unnecessary biopsies and improving patient outcomes by accurately identifying those needing aggressive treatment versus those suitable for observation. This review paper will explore the development, validation, and clinical implications of this novel urine test, highlighting its potential to transform prostate cancer diagnostics and patient management.
 
Keywords: 
Prostate Cancer; Prostate Specific Antigen (PSA); Urine Test; Genomic Analysis; Diagnostic Accuracy; High-Risk Cancer. 
 
Full text article in PDF: 
 
Copyright information: 

Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0